VRTX · News · 20260923N

Product / Drug Pipeline Progress

VERTEX PHARMACEUTICALS INC / MA · 2026-09-23 · Importance 51 · Surprise 74 · In source text

Vertex reported positive Phase IIb AMPLIFIED results for inaxaplin in patients with APOL1-mediated kidney disease (AMKD), including patients with modest proteinuria and type 2 diabetes. Inaxaplin produced a 42.7% reduction in a proteinuria measure in one patient cohort and was well tolerated across both cohorts. Vertex has completed enrollment in the pivotal Phase 2/3 AMPLITUDE trial, with interim data expected in early 2027. The results support inaxaplin’s potential as a treatment targeting the underlying cause of AMKD.

Key facts

• Interim data from the Phase 2/3 AMPLITUDE trial is expected in early 2027. source
• VRTX is targeting interim results from the AMPLITUDE study in early 2027. source
• Vertex Pharmaceuticals announced positive results from its Phase IIb AMPLIFIED trial for inaxaplin, treating APOL1-mediated kidney disease (AMKD) in patients with modest proteinuria and type 2 diabetes. source
• VRTX completed AMPLITUDE enrollment. source
• Vertex reported a 42.7 percent reduction in a proteinuria measure in one patient group. source
• The drug demonstrated significant reductions in proteinuria and was well-tolerated across both cohorts. source
• Vertex Pharma stock (VRTX) gained 3 percent ahead of the market open on September 23, 2026. source

Impact estimates